An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported today in the journal Nature Medicine by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their colleagues.
VRC (Vaccine Research Center) News Releases
Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In a perspective in The Journal of the American Medical Association, the experts highlight innovations that could significantly shorten the typical decades-long vaccine development timeline.
Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum. The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also may aid in vaccine design. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, led the research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle.
Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.
Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious DiseasesMaureen M. Goodenow, Ph.D., Director, Office of AIDS Research
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers report in Science today.
Vaccinations have begun in a multi-site Phase 2/2b clinical trial testing an experimental DNA vaccine designed to protect against disease caused by Zika infection. The vaccine was developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.
A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8. The research was conducted by a team of experts at NIAID, the Pirbright Institute based in the United Kingdom, and the Institute for Research in Biomedicine in Switzerland.
Two experimental Zika virus DNA vaccines developed by National Institutes of Health (NIH) scientists protected monkeys against Zika infection after two doses, according to a study published in Science. One of those vaccines is being evaluated in a Phase 1 human trial now under way in three U.S. locations to evaluate the vaccine’s safety and ability to generate immune responses in people.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants.
WHAT: Scientists have identified three types of vaccine-induced antibodies that can neutralize diverse strains of influenza virus that infect humans. The discovery will help guide development of a universal influenza vaccine, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID), and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH), and collaborators who conducted the research. The findings appear in the July 21st online edition of Cell.
A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell.
An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine.
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues have discovered that a single monoclonal antibody—a protein that attacks viruses—isolated from a human Ebola virus disease survivor protected non-human primates when given as late as five days after lethal Ebola infection.
A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report.
An experimental vaccine to protect against the mosquito-borne illness chikungunya is being tested in a Phase 2 trial sponsored by the National Institutes of Health.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs)
Scientists at the National Institutes of Health have created a protein that awakens resting immune cells infected with HIV and facilitates their destruction in laboratory studies.
Researchers funded by the National Institute of Allergy and Infectious Diseases have developed an investigational aerosol tuberculosis vaccine that induced potent immune responses in a small number of rhesus macaques and protected them against pulmonary infection with Mycobacterium tuberculosis .
A study by researchers helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract.
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
National Institute of Allergy and Infectious Diseases& scientists offer a historical perspective on the search for a safe, effective HIV vaccine and describe how they influence current promising approaches in HIV vaccinology.
An HIV vaccine research team led by scientists from the National Institutes of Health has engineered a protein to maintain the particular shape predicted to be most effective at stimulating the immune system to produce powerful antibodies against the virus.
A trio of studies describes advances toward the development of an HIV vaccine. The study teams demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies.
An extensive database identifying immune traits, such as how immune cell function is regulated at the genetic level in healthy people, is reported by researchers from the National Institutes of Health (NIH) and their collaborators.
Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses-the first to be completed in an African country-showed that they were safe and induced immune responses in healthy volunteers.
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a phase 1 clinical trial conducted by researchers from the National Institutes of Health.
New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects.
One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation.
Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.
An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in volunteers who participated in an early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases.
Scientists are pursuing injections or intravenous infusions of broadly neutralizing HIV antibodies (bNAbs) as a strategy for preventing HIV infection.
One strategy for developing a highly effective HIV vaccine is to learn how some HIV-infected people naturally develop antibodies that can stop a high percentage of global HIV strains from infecting human cells in the laboratory.
A scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2.